AXQ Capital LP Takes $1.54 Million Position in Johnson & Johnson (NYSE:JNJ)

AXQ Capital LP acquired a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 10,629 shares of the company's stock, valued at approximately $1,537,000. Johnson & Johnson accounts for about 0.7% of AXQ Capital LP's holdings, making the stock its 14th biggest position.

A number of other hedge funds have also recently modified their holdings of JNJ. Swedbank AB increased its holdings in Johnson & Johnson by 5.3% in the third quarter. Swedbank AB now owns 2,215,108 shares of the company's stock valued at $358,980,000 after buying an additional 111,570 shares in the last quarter. Principal Financial Group Inc. increased its stake in shares of Johnson & Johnson by 10.5% in the 3rd quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company's stock valued at $562,723,000 after purchasing an additional 329,473 shares in the last quarter. United Bank raised its holdings in Johnson & Johnson by 5.6% in the 3rd quarter. United Bank now owns 3,788 shares of the company's stock worth $614,000 after purchasing an additional 202 shares during the period. Segall Bryant & Hamill LLC purchased a new position in Johnson & Johnson during the third quarter worth approximately $5,883,000. Finally, Landscape Capital Management L.L.C. acquired a new stake in Johnson & Johnson in the third quarter valued at approximately $365,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Down 1.3 %

JNJ traded down $2.15 during trading hours on Tuesday, reaching $161.14. The company's stock had a trading volume of 7,455,754 shares, compared to its average volume of 7,086,516. The business's 50-day moving average is $157.70 and its 200-day moving average is $156.14. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The stock has a market cap of $388.32 billion, a PE ratio of 24.23, a P/E/G ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99.

Remove Ads

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to analysts' expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company's revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the business posted $2.29 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were issued a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.08%. Johnson & Johnson's dividend payout ratio is currently 74.59%.

Analysts Set New Price Targets

JNJ has been the topic of a number of recent analyst reports. Citigroup decreased their target price on Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a research report on Wednesday, December 11th. Argus upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Friday, January 24th. Leerink Partners decreased their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a research note on Thursday, January 23rd. Royal Bank of Canada reiterated an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, February 19th. Finally, Stifel Nicolaus reduced their target price on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus target price of $171.33.

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Robert J. Decker sold 6,999 shares of the business's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.